SIRS-Lab GmbH, Jena, Germany has introduced Siqnature, a new molecular test for the early prediction and monitoring of sepsis that yields information about the potential development of a systemic infection and monitors the progression of sepsis.
Clinical multi-center trials supervised by an international scientific advisory board will mark the projected scientific launch of the routine test in late 2008.
“We are proud to present this breakthrough approach in sepsis diagnostics,” said Stefan Russwurm, the company’s CEO PD. “After years of research and the successful implementation of the VYOO pathogen detection kit, Siqnature is the cornerstone to fulfill SIRS-Lab’s holistic diagnostic approach.”
The lab has identified transcriptomic biomarkers indicating sepsis and developed a proprietary biostatistical program that shows multiple messages in one score. The test result provides information about the existence and severity of a systemic infection.
The first clinical validation was performed by the lab’s clinical partners in the sepsis-cluster Jena. A large microarray study overseen by Professor Konrad Reinhart, Jena University Hospital, includes the data of 600 patients.
Biomarkers may aid in the diagnosis of sepsis, is a life-threatening systemic infection and one of the main causes of death in hospitals worldwide.
